PubMed Health⌕ Search

PubMed · 12935251

Complex magnetohydrodynamic low-Reynolds-number flows.

Abstract

The interaction between electric currents and a magnetic field is used to produce body (Lorentz) forces in electrolyte solutions. By appropriate patterning of the electrodes, one can conveniently control the direction and magnitude of the electric currents and induce spatially and temporally complicated flow patterns. This capability is useful, not only for fundamental flow studies, but also for inducing fluid flow and stirring in minute devices in which the incorporation of moving components may be difficult. This paper focuses on a theoretical and experimental study of magnetohydrodynamic flows in a conduit with a rectangular cross section. The conduit is equipped with individually controlled electrodes uniformly spaced at a pitch L. The electrodes are aligned transversely to the conduit's axis. The entire device is subjected to a uniform magnetic field. The electrodes are divided into two groups A and C in such a way that there is an electrode of group C between any two electrodes of group A. We denote the various A and C electrodes with subscripts, i.e., A(i) and C(i), where i=0,+/-1,+/-2, .... When positive and negative potentials are, respectively, applied to the even and odd numbered A electrodes, opposing electric currents are induced on the right and left hand sides of each A electrode. These currents generate transverse forces that drive cellular convection in the conduit. We refer to the resulting flow pattern as A. When electrodes of group C are activated, a similar flow pattern results, albeit shifted in space. We refer to this flow pattern as C. By alternating periodically between patterns A and C, one induces Lagrangian chaos. Such chaotic advection may be beneficial for stirring fluids, particularly in microfluidic devices. Since the flow patterns A and C are shifted in space, they also provide a mechanism for Lagrangian drift that allows net migration of passive tracers along the conduit's length.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Yu Xiang, Haim H Bau. 2003-07-28. Complex magnetohydrodynamic low-Reynolds-number flows.. https://doi.org/10.1103/physreve.68.016312

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗